SPTBN5

Across TCGA pan-cancer cohorts, SPTBN5 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated SPTBN5 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SPTBN5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPTBN5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and BRCA are the cancer types where SPTBN5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.050	0.570	<.001	24	view →
UCEC	DFS	Median	II,III,IV	0.849	0.425	.019	24	view →
BRCA	DFS	Median	III,IV	0.093	0.880	<.001	22	view →
LUAD	DFS	Median	II,III,IV	0.383	0.686	.003	22	view →
LUSC	OS	Median	II,III,IV	0.431	0.747	.007	12	view →
LIHC	OS	Median	II,III,IV	0.178	0.695	.010	12	view →
READ	DFS	Median	III,IV	0.059	0.761	<.001	11	view →
SCLC	DFS	Median	II,III,IV	0.219	0.609	.016	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
ACC	DFS	Median	All	0.112	0.544	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

SPTBN5–HNSC (DFS)

Open the HNSC breakdown →